NASDAQ:OTIC Otonomy (OTIC) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0085▼$0.008550-Day Range$0.01▼$0.1252-Week Range$0.01▼$2.54VolumeN/AAverage Volume937,525 shsMarket Capitalization$582,479.50P/E RatioN/ADividend YieldN/APrice Target$0.50 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Otonomy (NASDAQ:OTIC) StockOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Read More Receive OTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter. Email Address OTIC Stock News HeadlinesMay 10, 2023 | americanbankingnews.comOtonomy (NASDAQ:OTIC) Receives New Coverage from Analysts at StockNews.comApril 29, 2023 | americanbankingnews.comOtonomy (NASDAQ:OTIC) vs. Mainz Biomed (NASDAQ:MYNZ) Head to Head AnalysisMay 28, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost.April 24, 2023 | americanbankingnews.comOtonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.comApril 17, 2023 | americanbankingnews.comOtonomy (NASDAQ:OTIC) Now Covered by StockNews.comJanuary 23, 2023 | finance.yahoo.comOtonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo FinanceDecember 21, 2022 | finanznachrichten.deOtonomy, Inc.: Otonomy Provides Corporate UpdateDecember 19, 2022 | finance.yahoo.comOtonomy Provides Corporate UpdateMay 28, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost.November 30, 2022 | investorplace.com5 Investors Betting Big on Otonomy (OTIC) StockNovember 29, 2022 | investorplace.comWhy Is Otonomy (OTIC) Stock Up 97% Today?November 10, 2022 | finance.yahoo.comOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 6, 2022 | reuters.comOTIC.OQ - Otonomy Inc | Stock Price & Latest News | ReutersOctober 14, 2022 | marketscreener.comOTONOMY, INC. : Results of Operations and Financial Condition (form 8-K) - Marketscreener.comOctober 13, 2022 | investing.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% By Investing.com - Investing.comOctober 13, 2022 | finance.yahoo.comLianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial - Yahoo FinanceOctober 13, 2022 | streetinsider.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% - StreetInsider.comOctober 13, 2022 | benzinga.comOtonomy shares are trading lower after the company reported higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline. - Otonomy (NASDAQ:OTIC) - BenzingaOctober 13, 2022 | marketscreener.comOtonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive - Marketscreener.comOctober 13, 2022 | benzinga.comWhy Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday’s Mid- - BenzingaOctober 13, 2022 | marketscreener.comOtonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss - Marketscreener.comOctober 13, 2022 | globenewswire.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - GlobeNewswireOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing LossOctober 7, 2022 | reuters.comOTIC.O - Otonomy Inc | Stock Price & Latest News | ReutersSeptember 27, 2022 | marketscreener.comAPPLIED GENETIC TECHNOLOGIES CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comSeptember 17, 2022 | marketscreener.comOTONOMY, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.comSee More Headlines Receive OTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter. Email Address OTIC Company Calendar Last Earnings11/10/2021Today5/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC CUSIPN/A CIK1493566 Webwww.otonomy.com Phone(619) 323-2200Fax619-291-9190Employees51Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.50 High Stock Price Forecast$0.50 Low Stock Price Forecast$0.50 Forecasted Upside/Downside+5,782.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-137.86% Return on Assets-68.50% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual Sales$130,000.00 Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.01Miscellaneous Outstanding Shares68,527,000Free Float67,780,000Market Cap$582,479.50 OptionableOptionable Beta1.54 Key ExecutivesPaul E. CayerPresident, CFO, Secretary & Chief Business OfficerAnna StepannenkoVice President -Technical operationsFabrice PiuVice President-Research & Preclinical DevelopmentDavid SkarinskyVice President-ClinicalJeffery J. AndersonVice President-Clinical SciencesKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCTricidaNASDAQ:TCDAQLannettNYSE:LCINPLx PharmaNASDAQ:PLXPAltamira TherapeuticsNASDAQ:CYTOView All CompetitorsInsidersVickie L CappsSold 42,242 sharesTotal: $4,224.20 ($0.10/share)View All Insider Transactions OTIC Stock - Frequently Asked Questions Should I buy or sell Otonomy stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares. View OTIC analyst ratings or view top-rated stocks. What is Otonomy's stock price forecast for 2023? 2 brokers have issued 1 year price targets for Otonomy's shares. Their OTIC share price forecasts range from $0.50 to $0.50. On average, they anticipate the company's stock price to reach $0.50 in the next twelve months. This suggests a possible upside of 5,782.4% from the stock's current price. View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts. How were Otonomy's earnings last quarter? Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.19). During the same quarter in the prior year, the company earned ($0.22) EPS. What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $0.01. How much money does Otonomy make? Otonomy (NASDAQ:OTIC) has a market capitalization of $582,479.50 and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190. This page (NASDAQ:OTIC) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Otonomy, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.